CRISPR Therapeutics’ $280 Million Equity Issuance

Walder Wyss advised CRISPR Therapeutics on the issuance. CRISPR Therapeutics AG (NASDAQ: CRSP), a Switzerland-based biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

CRISPR Therapeutics’ Collaboration Agreement with Vertex Pharmaceuticals

Goodwin Procter LLP advised CRISPR Therapeutics on the deal. CRISPR Therapeutics (NASDAQ: CRSP) announced its collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to develop, manufacture, and...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

CRISPR Therapeutics’ Collaboration Agreement with Vertex Pharmaceuticals

Goodwin Procter LLP advised CRISPR Therapeutics on the deal. CRISPR Therapeutics (NASDAQ: CRSP) announced its collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to develop, manufacture, and...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here